Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

Table 1 Baseline characteristics pre- and post-matching

Baseline characteristics ^a	RADIANT-3 study sample		A6181111
Baseline characteristics ^a	Pre-match	Post-match	As reported
Median age (years)^b	58.0	56.5	56.5
Age > 64 years	27.4	26.3	26.3
Female	44.9	52.0	52.0
WHO or ECOG^c performance status of 0	68.8^d	55.0	55.0
Time since diagnosis ≥3 years	46.7	48.0	48.0
Number of disease sites
1	28.2	31.4	31.4
2	36.8	33.7	33.7
≥3	35.0	34.9	34.9
Presence of distant metastases	96.2	94.7	94.7
Previous somatostatin analogues	49.2^d	36.3	36.3
Previous systemic chemotherapy	48.7^d	69.0	69.0

Notes:
^aReported as percentages, unless otherwise noted.
^bFor A6181111, 56.5 is the midpoint between reported medians on the active (56) and placebo (57) arms.
^cAn ECOG performance status of 0 was equated to a WHO performance status of 0.
^d P < 0.05 for comparison vs. A6181111.

ISSN: 2162-3619